Pathak, Atul
Poulter, Neil R.
Kavanagh, Michael
Kreutz, Reinhold
Burnier, Michel
Funding for this research was provided by:
Servier
Article History
Accepted: 26 September 2021
First Online: 9 November 2021
Declarations
:
: The satellite symposium and medical writing assistance for the development of this manuscript were funded by Servier.
: M. Burnier has received honoraria and research grants from Servier, Menarini, Bayer, Idorsia, and Vifor Pharma. N. Poulter has received financial support from several pharmaceutical companies that manufacture BP-lowering agents for consultancy fees (Servier), research projects and staff (Servier, Pfizer), and arranging and speaking at educational meetings (AstraZeneca, Lri Therapharma, Napi, Servier, Sanofi, Eva Pharma, and Pfizer). He holds no stocks or shares in any such companies<i>.</i> A. Pathak was a speaker at the symposium and is President of the European Society for Patient Care and President of the French Society of Hypertension. M. Kavanagh was a speaker at the symposium as a patient advocate for hypertension on behalf of the Global Heart Hub Association, which received the funding from Servier. R. Kreutz has received honoraria for consultancy and lectures and support for research from Bayer Pharma, Berlin-Chemie Menarini, Daiichi Sankyo, Ferrer, Sanofi, and Servier.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: N. Poulter collated the slides that formed the basis of the text relating to MMM, of which he is the Chief Investigator, and read and approved drafts of this manuscript. A. Pathak contributed to the adherence and inertia section of the manuscript and revised and approved each draft. M. Burnier made a significant contribution to the adherence and inertia part of the manuscript and contributed to the revisions of the manuscript. M. Kavanagh read and approved drafts of this manuscript. R. Kreutz was a moderator of this ISH/ESH symposium and revised and approved drafts of this manuscript.